Skip to main content
Full access
Letter
Published Online: 1 November 1999

Treating Comorbid ADHD, Major Depression, and Panic

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: Attention-deficit/hyperactivity disorder (ADHD) increases one's risk for both major depression (MD) and an anxiety disorder by approximately 25%.1 Some individuals have all three. Therefore, we are proposing patients with such comorbidities should have their MD treated first, their anxiety disorder next, and finally be offered a noncombination, low-potency stimulant for ADHD.
Case Report
A 38-year-old man was initially diagnosed with MD by use of the Inventory to Diagnose Depression (IDD), scoring a 38 (0–10 is normal). A trial of sertraline 125 mg produced a remission (IDD<10).
His generalized anxiety partially decreased on the sertraline, as measured by Beck Anxiety Inventory's (BAI) decreasing from 28 to 20. His panic attacks, occurring at a frequency of twice per week, continued on the sertraline, although with reduced distress. Having failed a competent trial of extensive exposure and cognitive reconstructing panic therapy prior to our treatment, he was tried on clonazepam 0.25 mg three times a day, producing a stable BAI of 4 (normal), with no panic attacks for 2 months.
Despite his improvement, the patient still met criteria for adult ADHD, with a childhood onset at age 5. Two first-degree relatives had ADHD. Common standard diagnostic scales such as the Brown Adult ADHD Scale, the Wender Utah Retrospective Scale, and the Semi-Structured Adult Interview for ADHD all confirmed his mental status exam and reported history.
The patient asked for a trial off clonazepam to “keep his medication simple.” He was weaned off clonazepam, and his BAI rose to a “tolerable” 15, with no clear panic attacks. A trial of 5 mg Adderall, at breakfast and at 2:00 p.m., caused clear, repeated anxiety spikes 4 hours after each dose. Since Adderall represents two stimulants or four different amphetamine compounds, one or more may have been exerting marked stimulation at the 4-hour mark.
Back on his clonazepam, the patient tried methylphenidate 7.5 mg tid (he had “failed” dextroamphetamine as a teenager). He had an 85% reduction of his ADHD symptoms, with no increase in anxiety.
This case suggests that one should treat ADHD with comorbid anxiety with a low-potency noncombination stimulant, to prevent sensitivity to stimulants.

References

1.
Barkley RA: Comorbid disorders, social relations, and subtyping, in Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York, Guilford, 1998, pp 139–163

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 516
PubMed: 10570768

History

Published online: 1 November 1999
Published in print: November 1999

Authors

Details

James L. Schaller, M.D., M.A.R.
West Chester Child and Adult Psychiatry Center, Downingtown, PA
David Behar, M.D.
Eastern Pennsylvania Psychiatric Institute, Philadelphia, PA

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share